G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose against upper respiratory infections

Results of collaboration between G.ST Antivirals and Takeda Global Pathogen Safety are published in The Journal of Virus Eradication and substantiate efficacy of 2-Deoxyglucose against respiratory tract pathogens

G.ST Antivirals nominated among the top 10 for the Bridging Science & Business Award of the Rudolf Sallinger Foundation

G.ST Antivirals reaches a major milestone in the development of its lead asset and begins clinical phase I at the Vienna General Hospital

G.ST Antivirals to expand its innovative host cell-based treatment approach to COPD exacerbations after succeeding in highly competitive Life science call of the Vienna Business Agency

CEO and Co-founder Guido Gualdoni talked at the Gründer&Zünder Podcast about the exciting path from scientific findings to starting a biotech company

G.ST Antiviral's founder gave an encouraging interview about the obstacles and joys of founding a university spin-off (in German)

Founders of G.ST Antivirals Guido Gualdoni and Johannes Stöckl are “Inventors of the Year 2020” of the Medical University of Vienna

G.ST Antivirals among the nominees for the Phönix Gründerpreis of the Austrian Promotional Bank (AWS) in the category Spin-off

Viennese biotech startup G.ST Antivirals gets funding for viral disease therapies

G.ST Antivirals and Takeda start research cooperation on antivirals against COVID-19